|
Stomach Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The real-time quantitative RT-PCR analysis of the CEA and/or CK20 transcripts in the peritoneal lavage fluid is useful for predicting the peritoneal recurrence in patients who are undergoing a curative resection for gastric cancer.
|
17667927 |
2007 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In patients with stage I GC, the sensitivity of serum olfactomedin 4 (25%) and Reg IV (35%) was superior to that of CA19-9 (5%) or CEA (3%).
|
19670418 |
2009 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Whereas NLR, PLR and CEA are known to help distinguish GC from benign gastric lesions, combining CEA with PLR or NLR offers better diagnostic value for GC than any of them used alone.
|
29476736 |
2018 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
There were significant differences in age, gender, carcinoembryonic antigen (CEA), carbohydrate antigen (CA) 153 between gastric cancer and healthy controls (<i>P</i><0.05).
|
31308753 |
2019 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Compared with CEA, CA19-9, CA72-4 and CA50, CFD may prove to be a better biomarker for the screening of GC, thus providing a sensitive biomarker for screening and monitoring progression of GC.
|
28903321 |
2017 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This review systematically summarizes the three most commonly used biomarkers of GC (e.g., CEA, CA19-9, and CA72-4) and addresses two categories of potential molecular biomarkers for the diagnosis of GC: microRNA and methylated DNA.
|
26559090 |
2015 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, the expression of miR‑130a in plasma in gastric cancer patients was upregulated and diagnostic value for gastric cancer of miR-130a is more effective than the tumor markers carcinoembryonic antigen (CEA) and CA-199. miR-130a directly targeted runt‑related transcription factor 3 (RUNX3) and promoted gastric cancer tumorigenesis by targeting RUNX3. miR-130a may therefore be a useful marker for the diagnosis and prognosis of gastric cancer.
|
26134263 |
2015 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, REG4 may be not only a prognostic indicator but also a better serum marker than carcinoembryonic antigen and carbohydrate antigen 19-9 for early diagnosis of gastric cancer.
|
21419474 |
2011 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The concentrations of serum CEA in gastric cancer were higher than normal controls.
|
12854131 |
2003 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We have previously demonstrated the prognostic factors in gastric cancer including growth factors and their receptors and intra-peritoneal CEA (1,2).
|
12820444 |
2003 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, combined use of MPV, PDW and CEA can accurately distinguish gastric cancer from gastric ulcer and controls.
|
28977972 |
2017 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results demonstrate that CEACAM5 is a promising biomarker for GC prewarning and prognostic evaluation.
|
26374829 |
2015 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Multivariate survival analysis showed that CEA (OR = 4.924), and T category (OR = 2.214) were significant prognostic factors for stage pN<sub>0</sub> GC (all <i>P</i> < 0.05).
|
29358864 |
2017 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Currently, CEA, CA50 and CA72-4 are commonly used as tumor markers for gastric cancer by immunoassays.
|
30303958 |
2018 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We developed a dual-label time-resolved fluoroimmunoassay (TRFIA) to simultaneously detect carbohydrate antigen 125 (CA125) and carcinoembryonic antigen (CEA) in human serum to aid the diagnosis and prognosis of gastric cancer.
|
29729233 |
2018 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study aims to evaluate and compare the diagnostic accuracy of 5 common tumor biomarkers (CA19-9, CA125, PG, IncRNA, and DNA methylation) and CEA and their combinations for diagnosing gastric cancer through network meta-analysis method, and to rank these tests using a superiority index.
|
29742692 |
2018 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
For 15 cases of peritoneal dissemination (seven cases were cytologically positive), DDC was positive in 13 cases (87% sensitivity), but CEA failed to detect micrometastases in four cases (73% sensitivity), indicating that DDC is in some cases superior to CEA for the detection of peritoneal micrometastases of gastric cancer in terms of sensitivity as well as specificity, especially for poorly differentiated adenocarcinomas.
|
14760382 |
2004 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Data from receiver operating characteristic (ROC) curve analysis disclosed a better diagnostic accuracy of plasma DEK than carcinoembryonic antigen (CEA), carbohydrate antigen 19.9 (CA 19.9), and C-reactive protein (CRP), highlighting its potential as an effective plasma biomarker for GC.
|
31766266 |
2019 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Carcinoembryonic antigen-targeted selective gene therapy for gastric cancer through FZ33 fiber-modified adenovirus vectors.
|
16778108 |
2006 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Combination of ADAM 8 and CEA further increased the diagnostic accuracy to predict GC (sensitivity, 81.8%; specificity, 84.0%).
|
31347325 |
2019 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to construct a phage library of human single-chain antibodies associated with gastric cancer and screen such a library for CEA binding scFv.
|
11796012 |
2002 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Detection of peritoneal micrometastases of gastric carcinoma with green fluorescent protein and carcinoembryonic antigen promoter.
|
11454709 |
2001 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
sLAG3 in PB was poorly expressed and its expression was positively correlated with IL-12 and IFN-γ expression in GC patients. sLAG3 was proved to have a higher diagnostic value than CEA in GC.
|
30223387 |
2018 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
AdCEA-CD/5FC system may provide a novel approach to treatment of i.p. disseminated gastric cancer.
|
9331089 |
1997 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Results:</b> Univariate analysis showed that the factors related to PD in GC were: carbohydrate antigen (CA) 125 (<i>P</i> < 0.0001), CA19-9 (<i>P</i> < 0.0001), CA72-4 (<i>P</i> < 0.0001), FLR (<i>P</i> < 0.0001), neutrophil-to-lymphocyte ratio (NLR) (<i>P</i> < 0.0001), albumin-to- lymphocyte ratio (ALR) (<i>P</i> < 0.0001), platelet-to-lymphocyte ratio (PLR) (<i>P</i> = 0.013), and carcinoembryonic antigen (CEA) (<i>P</i> = 0.031).
|
31750248 |
2019 |